{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurofibromas&page=2",
    "query": {
      "condition": "Neurofibromas",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurofibromas&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:00:59.530Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06961565",
      "title": "PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NF1 Mutation",
        "Neurofibroma Plexiform",
        "Neurofibroma, Plexiform",
        "Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)",
        "Neurofibromatosis Type 1 (NF1)"
      ],
      "interventions": [
        {
          "name": "PAS-004 Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pasithea Therapeutics Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2025-05-30",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-05-22T04:00:59.530Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06961565"
    },
    {
      "nct_id": "NCT01347307",
      "title": "Stereotactic Body Radiotherapy for Spine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Metastases",
        "Vertebral Metastases",
        "Benign Spinal Tumors",
        "Chordoma",
        "Meningioma",
        "Schwannoma",
        "Neurofibroma",
        "Paragangliomas",
        "Arteriovenous Malformations"
      ],
      "interventions": [
        {
          "name": "SBRT for Benign Extradural Spine Tumors",
          "type": "RADIATION"
        },
        {
          "name": "SBRT for Vertebral/Paraspinal Metastases",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Mercy Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2008-09",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2020-06-18",
      "last_synced_at": "2026-05-22T04:00:59.530Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01347307"
    },
    {
      "nct_id": "NCT03880123",
      "title": "Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liposarcoma",
        "Malignant Peripheral Nerve Sheath Tumors",
        "Alveolar Soft Part Sarcoma",
        "Ewing Sarcoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Ixazomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matthew Ingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-11",
      "completion_date": "2020-11-24",
      "has_results": false,
      "last_update_posted_date": "2020-11-27",
      "last_synced_at": "2026-05-22T04:00:59.530Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03880123"
    },
    {
      "nct_id": "NCT05377008",
      "title": "Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neurocognitive Deficit",
        "Mental Health Impairment",
        "Neurofibromatosis 1"
      ],
      "interventions": [
        {
          "name": "OPTIMAL-SSI",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "6 Years to 16 Years"
      },
      "enrollment_count": 38,
      "start_date": "2022-05-13",
      "completion_date": "2023-05-05",
      "has_results": false,
      "last_update_posted_date": "2023-09-22",
      "last_synced_at": "2026-05-22T04:00:59.530Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05377008"
    },
    {
      "nct_id": "NCT00508235",
      "title": "Quality of Friendships in Children With Neurofibromatosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurofibromatosis"
      ],
      "interventions": [
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "8 Years to 18 Years"
      },
      "enrollment_count": 61,
      "start_date": "2004-12",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-05-22T04:00:59.530Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00508235"
    },
    {
      "nct_id": "NCT01968590",
      "title": "Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis Type 1 (NF1)"
      ],
      "interventions": [
        {
          "name": "Cholecalciferol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "25 Years to 40 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-08-16",
      "completion_date": "2022-01-01",
      "has_results": false,
      "last_update_posted_date": "2022-05-25",
      "last_synced_at": "2026-05-22T04:00:59.530Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01968590"
    },
    {
      "nct_id": "NCT01633008",
      "title": "Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neurofibromatosis"
      ],
      "interventions": [
        {
          "name": "ACT Workshop",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "12 Years to 99 Years"
      },
      "enrollment_count": 28,
      "start_date": "2012-06-15",
      "completion_date": "2017-01-10",
      "has_results": false,
      "last_update_posted_date": "2019-09-30",
      "last_synced_at": "2026-05-22T04:00:59.530Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01633008"
    },
    {
      "nct_id": "NCT01275586",
      "title": "Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neurofibromatosis",
        "NF1",
        "Neurofibromas"
      ],
      "interventions": [
        {
          "name": "Tasigna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2011-01",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2017-04-12",
      "last_synced_at": "2026-05-22T04:00:59.530Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01275586"
    },
    {
      "nct_id": "NCT03719430",
      "title": "APX005M and Doxorubicin in Advanced Sarcoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "APX005M",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexander Z. Wei, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2019-03-20",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-05-22T04:00:59.530Z",
      "location_count": 3,
      "location_summary": "Duarte, California • St Louis, Missouri • New York, New York",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03719430"
    },
    {
      "nct_id": "NCT01089101",
      "title": "Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Low Grade Glioma",
        "Recurrent Childhood Pilocytic Astrocytoma",
        "Recurrent Neurofibromatosis Type 1",
        "Recurrent Visual Pathway Glioma",
        "Refractory Neurofibromatosis Type 1",
        "Refractory Visual Pathway Glioma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Selumetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 217,
      "start_date": "2010-07-07",
      "completion_date": "2027-03-18",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T04:00:59.530Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01089101"
    }
  ]
}